ERBB2 and pachyonychia congenita: Another study analyzed 50 bone metastatic PC cases using IHC and found HER2 overexpression (>1+) in 42% of samples while the PC-specific survival and nonrecurrence rates were significantly lower in the HER2-positive group than in the -negative group (p = 0.0084 and p = 0.0485, respectively).